The landscape for cell and gene therapies has been evolving over the past few years with a rise in available treatments for rare and life-threatening diseases in the last year alone. This is despite generally high costs of R&D and manufacturing, coupled with the infancy of scientific understanding compared to other areas of science.
Despite the increasing volume of gene therapy assets targeting hematological malignancies, significant market potential exists, driven by the complexities in treatment-related adverse events among approved products – opportunities for further differentiation thus exists for novel therapies.
As cell and gene therapies move into indications with larger disease burdens, manufacturers will have a myriad of factors to consider, including the holistic value of a potentially curative therapy on already strained healthcare systems, payer price-sensitivity, and a potentially depleting patient population.
The curative potential of cell and gene therapies presents paradigm-shifting opportunities and challenges to the biopharma industry, requiring CI teams with deep therapy area knowledge and access to robust secondary and primary insights to support critical strategic decision-making at key inflection points.
